New drug combo aims to fight Hard-to-Treat vulvar cancer
NCT ID NCT07290894
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink or control vulvar cancer that cannot be surgically removed. About 80 participants will receive the combination in 21-day cycles. The study will measure tumor response and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab and Lenvatinib
- What this could lead to
- If successful, this combination could offer a new treatment option to shrink or control vulvar cancer that cannot be removed by surgery.
- What could go wrong
- This is an early Phase 2 trial with a small number of participants. The drugs may cause side effects, and it is not yet known if they will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVA CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nation Cancer Institute of Naples, Division of Medical Oncology - Uro-Gynecology Department, Naples
RECRUITINGNaples, 80131, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to shrink vulvar tumors before surgery
- Blood test and patient surveys aim to outsmart vulva cancer recurrence
- Could a single dye replace the standard two-step test for vulvar cancer spread?
- New combo therapy shows promise for Hard-to-Treat vulvar cancer
- New smart chemo targets tumors, spares healthy tissue
- Supercharged immune cells take on HPV cancers